In this JAMA Health Forum column, KFF Executive Vice President Larry Levitt explores why the Trump administration and Republican majorities in Congress are likely to pursue budget cuts in Medicaid and the Affordable Care Act.
“We should soon know whether Novo Nordisk’s semaglutide will be subject to negotiation next year. If so, Medicare’s negotiated price would be available to people with Medicare starting in January 2027, which could help to bring down the cost of expanding coverage for anti-obesity medications, both for Medicare and for beneficiaries who use this drug.”
President-elect Trump has pledged to restrict and eliminate legal immigration pathways and deport millions of immigrants. In a new analysis, we look at the key changes to immigration policies that President-elect Trump may pursue in his new administration based on his previous record and campaign statements, as well as the implications of such changes.
A new KFF analysis finds higher Medicare spending among people who switched from Medicare Advantage to traditional Medicare than for similar beneficiaries who were in traditional Medicare all along. Medicare spent an average of 27% more on such beneficiaries, which amounts to a difference of $2,585 in Medicare spending per person, on average, between the two groups in 2022.
Georgia’s ability to process applications for Medicaid and other public benefits has lagged since the launch of Republican Gov. Brian Kemp’s “Pathways” Medicaid work requirement, leaving Georgia with persistently slow Medicaid application processing times.
Last week, 43% correctly answered that ACA enrollee premium payments are expected to increase by 75% if enhanced subsidies are not renewed by Congress.
By what amount does CMS estimate that Medicare spending will increase over 10 years due to the possible coverage of anti-obesity medications, as recently proposed by the Biden administration?
